Abstract 351P
Background
Aortic stenosis is the most common valvular complication of mediastinal radiotherapy. In 2016 was shown that not only radiotherapy but chemotherapy with anthracyclines alone may provoke the development of valvular heart diseases (VHD). But there are still not clear time frames of VHD development.
Methods
We present a single-center retrospective analysis of a cohort with breast cancer history who were treated in cardiology departments. Total 91 patients were included in this study. ECHO data and time till first symptoms and surgical treatment were assessed in all patients.
Results
Different VHD were revealed in 48.35% (n=44) of patients. Among them 54.5% (n=24) had aortic stenosis, 34.1% (n=15) – mitral regurgitation, 4.5% (n=2) – mitral stenosis with regurgitation, 2.3% (n=1) – isolated aortic regurgitation and the same number of isolated mitral stenosis. During 15 months 25 patients were undergoing surgical treatment. In 2 of them VHD was first diagnosed before cancer treatment, so they weren’t included in the subsequent analysis. The oncological age in operated patients was 60 [42; 68] years. The time till first signs of VHD was 8 [4; 16.5] years. In all patients dyspnea was presented, 39% of patients had angina and only in 21.7% had presyncopes and syncopes. The median time from oncological age till surgery was 11 [7; 22] years. We also revealed correlation between oncological age and time till first VHD signs and surgical treatment (r = -0.76 and r = -0.71 respectively).
Conclusions
Given the widespread prevalence of degenerative aortic stenosis in older age patients, it is advisable to assess valves condition not only before radiation and chemotherapy but also recommend more frequent echocardiographic monitoring after, as well as use of new visualization techniques, such as CT (calcium score) and 18F-NaF PET-CT (as marker of calcification).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
223P - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Karim Fizazi
Session: e-Poster Display Session
224P - Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study
Presenter: Atul Batra
Session: e-Poster Display Session
225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Presenter: Michael Fernando
Session: e-Poster Display Session
226P - Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Andrew Jensen
Session: e-Poster Display Session
227P - Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Presenter: Ulka Vaishampayan
Session: e-Poster Display Session
228P - Symptoms and impacts of metastatic castration-resistant prostate cancer (mCRPC) among Japanese patients designated to receive Ra-223
Presenter: Hiroji Uemura
Session: e-Poster Display Session
229P - Expanding the role of supervised exercise on fatigue in prostate cancer patient receiving androgen deprivation therapy: A meta-analysis of randomized controlled trial
Presenter: Niwanda Yogiswara
Session: e-Poster Display Session
230P - Molecular profiling and clinical characteristics of Chinese patients with prostate cancer
Presenter: Ranlu Liu
Session: e-Poster Display Session
231P - Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Presenter: Jeffrey Goh
Session: e-Poster Display Session
232P - Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
Presenter: Rachel Raju
Session: e-Poster Display Session